Recently, a systematic pan-tumor analyses investigated ICB-response biomarkers in a cohort of over 1000 ICB-treated patients from 12 individual studies, consisting of 7 tumor types, namely urothelial, head and neck, renal, colorectal, breast, non-small cell lung cancer and melanoma, treated with 3 distinct ICB-classes (α-CTLA-4, PD-1, or PD-L1) [66]. This evidence concerns the gene CD274 and neoplasm.